Editorial
|
|
|
|
|
Massive quantities of oseltamivir have been sold, despite a lack of evidence about its efficacy
|
|
|
|
Marketing Authorisations
|
|
|
|
|
More dangerous than helpful for women with postmenopausal vulvovaginal disorders
|
|
|
|
|
|
|
|
|
|
|
|
For patients requiring permanent parenteral nutrition for short bowel syndrome
|
|
|
|
|
|
|
|
|
|
|
|
Do not use in men (or in women)
|
|
|
|
|
|
|
|
|
|
Toxic, and no proof of improved survival
|
|
|
|
|
|
|
|
|
|
After treatment failure: better than pegvisomant
|
|
|
|
|
|
|
|
|
|
A poor choice for analgesia
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
No justification to use this drug
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Overdose due to ultrarapid CYP2D6 metabolism
|
|
|
|
|
|
|
|
|
|
Patients should be warned about the risk
|
|
|
|
|
|
|
|
|
|
Increased risk of hospital admission
|
|
|
|
Reviews
|
|
|
|
|
Codeine, dihydrocodeine and tramadol: no less risky than morphine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Partial protection of mothers and infants
|
|
|
|
Outlook
|
|
|
|
|
No reason to recommend its widespread use
|
|
|
|
|
|
|
|
|
|